Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, First-in-human, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

Next Previous
X
Search
Trial Profile

An Open-label, First-in-human, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elimusertib (Primary) ; Radium 223 chloride
  • Indications Advanced breast cancer; Carcinoma; Cervical cancer; Colon cancer; Endometrial cancer; Fallopian tube cancer; HER2 negative breast cancer; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Rectal cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Bayer

    • Most Recent Events

    • 10 Oct 2023 Status changed from recruiting to completed.
    • 26 May 2023 Planned End Date changed from 19 Apr 2024 to 19 Apr 2025.
    • 07 Nov 2022 Status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top